Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Refractory EBV-HLH in PTEN Hamartoma Tumor Syndrome Despite Dual Checkpoint Blockade | Synapse
March 3, 2026
Refractory EBV-HLH in PTEN Hamartoma Tumor Syndrome Despite Dual Checkpoint Blockade
AG
Alexander Garcia
Johns Hopkins University
AT
Alyson Trillo
SA
Sally Azer
Ver todo
Puntos clave
Refractory EBV-HLH was observed despite treatment efficacy with checkpoint blockade, pointing to potential resistance mechanisms involved.
The analysis demonstrated that previous interventions failed to achieve sustained remission in the case of EBV-HLH within PTEN syndrome.
Observation utilized case documentation to explore outcomes following dual checkpoint blockade therapy in affected individuals.
The study highlights the complex interaction between therapy response and underlying genetic predisposition in PTEN hamartoma tumor syndrome.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Garcia et al. (Sun,) studied this question.
synapsesocial.com/papers/69a760a7c6e9836116a2d9e6
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.503